286 related articles for article (PubMed ID: 36342475)
21. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
[TBL] [Abstract][Full Text] [Related]
22. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Vranckx P; Valgimigli M; Odutayo A; Serruys PW; Hamm C; Steg PG; Heg D; Mc Fadden EP; Onuma Y; Benit E; Janssens L; Diletti R; Ferrario M; Huber K; Räber L; Windecker S; Jüni P;
J Am Heart Assoc; 2021 Sep; 10(18):e015560. PubMed ID: 34533034
[TBL] [Abstract][Full Text] [Related]
24. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD; Braunwald E; McCabe CH; Montalescot G; Ruzyllo W; Gottlieb S; Neumann FJ; Ardissino D; De Servi S; Murphy SA; Riesmeyer J; Weerakkody G; Gibson CM; Antman EM;
N Engl J Med; 2007 Nov; 357(20):2001-15. PubMed ID: 17982182
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
[TBL] [Abstract][Full Text] [Related]
26. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
27. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
[TBL] [Abstract][Full Text] [Related]
28. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.
Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662
[TBL] [Abstract][Full Text] [Related]
29. Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Tan BE; Wong PY; Baibhav B; Thakkar S; Azhar AZ; Rao M; Cheung JW
Curr Probl Cardiol; 2023 Aug; 48(8):101174. PubMed ID: 35341798
[TBL] [Abstract][Full Text] [Related]
30. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL;
Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723
[TBL] [Abstract][Full Text] [Related]
31. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.
Tang YD; Wang W; Yang M; Zhang K; Chen J; Qiao S; Yan H; Wu Y; Huang X; Xu B; Gao R; Yang Y;
Circulation; 2018 May; 137(21):2231-2245. PubMed ID: 29420189
[TBL] [Abstract][Full Text] [Related]
32. Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Ono K; Kadota K; Suwa S; Morishima I; Yoshida R; Hata Y; Akao M; Yagi M; Suematsu N; Morino Y; Yokomatsu T; Takamisawa I; Noda T; Doi M; Okayama H; Nakamura Y; Hibi K; Sakamoto H; Noguchi T; Kimura T;
J Am Coll Cardiol; 2024 Jan; 83(1):17-31. PubMed ID: 37879491
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Helft G; Le Feuvre C; Georges JL; Carrie D; Leclercq F; Eltchaninoff H; Furber A; Prunier F; Sebagh L; Cattan S; Cayla G; Vicaut E; Metzger JP
Trials; 2013 Feb; 14():56. PubMed ID: 23433461
[TBL] [Abstract][Full Text] [Related]
34. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Jiang M; You JHS
Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
[TBL] [Abstract][Full Text] [Related]
36. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
37. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Bossard M; Granger CB; Tanguay JF; Montalescot G; Faxon DP; Jolly SS; Widimsky P; Niemela K; Steg PG; Natarajan MK; Gao P; Fox KAA; Yusuf S; Mehta SR
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29101117
[TBL] [Abstract][Full Text] [Related]
38. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
[TBL] [Abstract][Full Text] [Related]
39. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
[TBL] [Abstract][Full Text] [Related]
40. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
